Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
2 findings from 1 review
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
2 findings from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).
1 finding from 1 review